Fundraising Fox
/Companies
Sign in

Clarametyx

Columbus, US · Founded 2020 · Delaware corporation · 4 known investors

Find your way into Clarametyx

Sign up to see every warm intro you have to Clarametyx

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Clarametyx team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.

BiotechHealthtechMedical Devices

Founders & leadership

DR
David RichardsNamed on SEC filing
PG
Peter G. KleinhenzNamed on SEC filing
ML
Michael LaymanNamed on SEC filingExecutive Officer at 1776
CB
Chuck BramlageNamed on SEC filing
LE
Larry EdwardsNamed on SEC filing
MT
Michael Triplett IINamed on SEC filing

Board

WBWilliam Baumel
William BaumelBoard directorManaging Director at Ohio Innovation Fund
WEWayne Embree
Wayne EmbreeBoard directorSenior Advisory Partner at Rev1 Ventures

Investors · 4

JobsOhio Ventureslisted by JobsOhio VenturesColumbus

How we know: JobsOhio Ventures's portfolio page · Not right? Tell us

Ohio Innovation Fundlisted by Ohio Innovation FundDublin · $500K – $4Mvia Faith Voinovich · led

How we know: Ohio Innovation Fund's portfolio page · funding news · press coverage · Not right? Tell us

Rev1 VenturesreportedColumbusvia Wayne Embree · board

How we know: board seat on SEC Form D · press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$27.5M disclosed across 1 round · 2024

▶$27.5MraisedJan 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David RichardsExecutive Officer
  • Peter G. KleinhenzDirector
  • Michael LaymanDirector
  • William BaumelDirector
  • Wayne EmbreeDirector
  • Chuck BramlageDirector
  • Larry EdwardsDirector
  • Michael Triplett IIDirector
Offering amount
$33.1M
Amount sold
$27.5M
First sale
Jan 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

CelmatixCelmatix Therapeutics developed a discovery portfolio focused on women's health, including therapeutic programs for infertility, endometriosis, and ovarian aging. The company's pipeline included an oral FSH receptor agonist, a JNK inhibitor, and AMH-targeting antibodies.
Pro MatixPromatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.

Companies working in the same space as Clarametyx.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Clarametyx Biosciences Receives Investment From Kineticos AMR Accelerator Fundfinsmes.com · Jan 2025Clarametyx Biosciences Raises $33M in Series A Financingfinsmes.com · Jan 2024Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections - Clarametyx Biosciencesclarametyx.com · Jan 2024

Frequently asked questions

What does Clarametyx do?
Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.
Who are Clarametyx's investors?
Clarametyx's investors include CincyTech, JobsOhio Ventures, Ohio Innovation Fund, Rev1 Ventures.
How much funding has Clarametyx raised?
Clarametyx has disclosed $27.5M raised across 1 round.
Where is Clarametyx headquartered?
Clarametyx is headquartered in Columbus, US.